Biomea Fusion (BMEA) Enterprise Value (2020 - 2026)
Biomea Fusion (BMEA) posted Enterprise Value of -$45.1 million for Q1 2026, up 19.26% sequentially from -$55.8 million in Q4 2025, and down 25.65% YoY from -$60.6 million in Q1 2025.
Biomea Fusion (BMEA) Enterprise Value (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Enterprise Value for 7 years, with the latest figure at -$45.1 million in Q1 2026.
- Quarterly Enterprise Value fell 25.65% year-over-year to -$45.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.1 million (down 25.65% YoY) and the FY2025 annual result came in at -$55.8 million, up 4.23% from the prior year.
- Enterprise Value rose to -$45.1 million in Q1 2026 per BMEA's latest filing, from -$55.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$35.9 million in Q1 2025 and troughed at -$222.9 million in Q2 2023.
- A 5-year average of -$111.4 million and a median of -$113.4 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value tumbled 263.17% in 2022, then soared 75.32% in 2025.
- Over 5 years, Enterprise Value stood at -$113.4 million in 2022, then sank by 56.29% to -$177.2 million in 2023, then surged by 67.12% to -$58.3 million in 2024, then advanced by 4.23% to -$55.8 million in 2025, then grew by 19.26% to -$45.1 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$45.1 million, -$55.8 million, and -$47.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | -35.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.19 Mn |
| Mar 31, 2026 | -45.06 Mn |
| Dec 31, 2025 | -55.81 Mn |
| Sep 30, 2025 | -47.01 Mn |
| Jun 30, 2025 | -56.59 Mn |
| Mar 31, 2025 | -35.86 Mn |
| Dec 31, 2024 | -58.28 Mn |
| Sep 30, 2024 | -88.32 Mn |
| Jun 30, 2024 | -113.66 Mn |
| Mar 31, 2024 | -145.29 Mn |
| Dec 31, 2023 | -177.24 Mn |
| Sep 30, 2023 | -199.09 Mn |
| Jun 30, 2023 | -222.91 Mn |
| Mar 31, 2023 | -86.65 Mn |
| Dec 31, 2022 | -113.40 Mn |
| Sep 30, 2022 | -133.81 Mn |
| Jun 30, 2022 | -149.98 Mn |
| Mar 31, 2022 | -165.16 Mn |
| Dec 31, 2021 | -173.87 Mn |
| Sep 30, 2021 | -157.25 Mn |